News

News Subscription

Nov 04. 2025 / Ad hoc announcement
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
Read more
Download
Sep 25. 2025 / Ad hoc announcement
Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam
Read more
Download
Sep 16. 2025 / Ad hoc announcement
Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Read more
Download
Aug 19. 2025 / Ad hoc announcement
Basilea on track with strong 2025 half-year results
Read more
Download
Aug 14. 2025 / Ad hoc announcement
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic
Read more
Download
Jul 29. 2025
Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections
Read more
Download
Jul 08. 2025 / Ad hoc announcement
Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Read more
Download
Jun 05. 2025
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea
Read more
Download
May 20. 2025
Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States
Read more
Download
Apr 24. 2025
Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea
Read more
Download